Skip to main content

Harwin Peter Evan's Form 4 filing

Dianthus Therapeutics, Inc. (DNTH) · filed Oct 3, 2023

Accession no.
0001104659-23-106378
Filed
Oct 3, 2023, 4:00 PM ET
Trade date
Sep 29, 2023
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 1 non-derivative transaction. Open-market purchases total $336.3K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Harwin Peter EvanCIK 0001663607Director, 10% Owner
Fairmount Funds Management LLCCIK 0001802528Director, 10% Owner
Kiselak TomasCIK 0001830177Director, 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 29, 2023Common StockPPurchaseAcquired+24,670$13.63F2+$336,252.11,928,503Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $13.45 to $13.645. The price reported above reflects the weighted average purchase price. The Reporting Persons hereby undertake to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

Remarks

Fairmount, Fund I, Fund II and Fairmount SPV III, LLC may each be deemed a director by deputization of the Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of the Issuer and is a Managing Member of Fairmount.

Read the full filing on SEC EDGAR (opens in a new tab)